TNFRSF9 and systemic lupus erythematosus: demonstrated that baricitinib treatment in 239 patients with SLE significantly reduced levels of several pro-inflammatory plasma markers, including CCL9, CXCL10, CD137, PD-L1, IL-6, and IL-12β (2).